Clinical Trials

Carcinoma, Non-Small-Cell Lung

NCT07020065 2026-04-15

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

156 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06632327 2026-04-07

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

Phase 3 Recruiting

1,100 enrolled

Lung Neoplasms

NCT03158129 2026-04-06

Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

Phase 2 Completed

101 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT05624996 2026-04-03

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Phase 3 Recruiting

474 enrolled

Lung Neoplasms

NCT07001618 2026-04-03

IMMUNOLIFE2

162 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06745882 2026-04-02

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

318 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06812871 2026-04-02

High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

Phase 2 Completed

46 enrolled

CNS

Meningeal Carcinomatosis

NCT05254184 2026-03-30

KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC

Phase 1 Recruiting

12 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06538038 2026-03-27

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

Recruiting

538 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04253964 2026-03-19

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

105 enrolled

Phase 4 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05689671 2026-03-10

ANTELOPE

136 enrolled

Non-Small Cell Lung Cancer Metastatic

NCT05335941 2026-03-04

A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma

10 enrolled

Genitourinary

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT05681195 2026-03-03

Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas

15 enrolled

Neoplasms, Recurrence

NCT06663306 2026-03-02

Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC

Phase 1 Recruiting

19 enrolled

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Carcinomatosis

NCT03774732 2026-02-25

NIRVANA-LUNG

327 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06630416 2026-02-24

Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors

64 enrolled

Genitourinary

Urinary Bladder Neoplasms, Neoplasm Metastasis

NCT03366766 2026-02-20

Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer

Phase 2 Terminated

14 enrolled 16 charts

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04837716 2026-02-19

Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer

12 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04892953 2026-02-19

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

51 enrolled

Lung Neoplasms

NCT07420439 2026-02-19

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

108 enrolled

Lung Diseases, Interstitial

NCT05715229 2026-02-18

G360-IIT

108 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07416058 2026-02-17

PHOENIX

61 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Adenocarcinoma of Lung

NCT03559049 2026-02-12

Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

Phase 1/2 Terminated

25 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT07405190 2026-02-12

Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC

46 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07234058 2026-02-11

LAG-MAPS

Other solid neoplasmThoracic

126 enrolled

Mesothelioma, Malignant

NCT03875144 2026-02-09

MESOTIP

Phase 2 Suspended

66 enrolled

Gynecologic

Peritoneal Neoplasms

NCT04297605 2026-02-09

Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

Phase 1 Recruiting

28 enrolled

Other solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung

NCT02662504 2026-02-05

MesoPDT

Phase 2 Completed

6 enrolled

Mesothelioma, Malignant, Mesothelioma

NCT07229339 2026-02-05

Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer

16 enrolled

Lung Non-Squamous Non-Small Cell Carcinoma

NCT04895735 2026-02-02

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

45 enrolled

Head & Neck

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

NCT07131319 2026-02-02

SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC

Phase 2/3 Recruiting

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04339218 2026-01-30

CRYOMUNE

Phase 3 Recruiting

214 enrolled

Adenocarcinoma of Lung

NCT06296745 2026-01-30

Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.

36 enrolled

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06484491 2026-01-30

HyDose

Phase NA Recruiting

87 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05500092 2026-01-28

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

17 enrolled

Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

NCT07365410 2026-01-26

Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

60 enrolled

Other solid neoplasmThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04334759 2026-01-22

DREAM3R

Phase 3 Completed

214 enrolled

Mesothelioma, Malignant, Mesothelioma

NCT05746481 2026-01-22

Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

Phase 2 Terminated

3 enrolled 12 charts

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04166487 2026-01-21

Plasma-Adapted First-Line Pembro In NSCLC

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06576635 2026-01-20

LUNG-05

Phase NA Recruiting

29 enrolled